logo

Sage Therapeutics, Inc. (SAGE)



Trade SAGE now with
  Date
  Headline
11/20/2018 7:34:41 AM Sage Therapeutics Receives Notification Of PDUFA Extension For ZULRESSO Injection
11/6/2018 6:37:52 AM Sage Therapeutics Q3 Net Loss $122.9 Mln Vs Net Loss $73.7 Mln Last Year
11/5/2018 6:34:34 AM Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/2/2018 7:18:32 AM Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss ZULRESSO Injection
9/6/2018 6:36:16 AM Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8/15/2018 6:00:46 AM Karuna Appoints Steven Paul As CEO
8/7/2018 6:35:06 AM Sage Therapeutics Q2 Net Loss $17.0 Mln Vs Loss Of $70.2 Mln Last Year
6/12/2018 6:32:24 AM Sage Announces Pivotal Phase 3 Trial Status For SAGE-217
5/30/2018 7:07:07 AM Sage Therapeutics: FDA Acceptance Of NDA Filing & Grant Of Priority Review For Brexanolone IV In Postpartum Depression
5/3/2018 6:37:56 AM Sage Therapeutics Q1 Net Loss $74.6 Mln Vs Loss Of $56.8 Mln Last Year
4/23/2018 7:04:15 AM Sage Therapeutics Submits NDA To US FDA For Intravenous Brexanolone In Treatment Of Postpartum Depression
2/22/2018 6:38:47 AM Sage Therapeutics Q4 Net Loss $69.4 Mln Vs Net Loss $55.9 Mln Last Year
2/8/2018 10:16:04 PM Sage Therapeutics Prices Offering Of 3.51 Mln Shares At $164.00/shr
2/7/2018 6:32:45 AM Sage Therapeutics Receives FDA Breakthrough Therapy Designation For SAGE-217 For Major Depressive Disorder
1/31/2018 6:08:07 AM Sage Therapeutics Announces Positive Results From Placebo-Controlled Trial; SAGE-217 Meets Primary Endpoint